Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital of Basel, Basel, Switzerland.
Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia/Department of Neurology, Box Hill Hospital, Monash University, Box Hill, VIC, Australia.
Mult Scler. 2018 Jun;24(7):963-973. doi: 10.1177/1352458517709619. Epub 2017 May 30.
Confirmed Expanded Disability Status Scale (EDSS) progression occurring after a fixed-study entry baseline is a common measure of disability increase in relapsing-remitting multiple sclerosis (RRMS) studies but may not detect all disability progression events, especially those unrelated to overt relapses.
To evaluate possible measures of disability progression unrelated to relapse using EDSS data over ≈5.5 years from the Tysabri Observational Program (TOP).
TOP is an ongoing, prospective, open-label study in RRMS patients receiving intravenous 300 mg natalizumab every 4 weeks. Measures of increasing disability were assessed using as a reference either study baseline score or a "roving" system that resets the reference score after ⩾24- or ⩾48-week confirmation of a new score.
This analysis included 5562 patients. Approximately 70% more EDSS progression events unrelated to relapse and 50% more EDSS worsening events overall were detected with a roving reference score (cumulative probability: 17.6% and 29.7%, respectively) than with a fixed reference baseline score (cumulative probability: 10.1% and 20.3%, respectively).
In this long-term observational RRMS dataset, a roving EDSS reference value was more efficient than a study baseline EDSS reference in detecting progression/worsening events unrelated to relapses and thus the transition to secondary progressive disease.
复发缓解型多发性硬化症(RRMS)研究中,固定研究入组基线后确诊的扩展残疾状况量表(EDSS)进展是衡量残疾加重的常用指标,但可能无法检测到所有的残疾进展事件,尤其是与明显复发无关的事件。
使用 Tysabri 观察计划(TOP)中约 5.5 年的 EDSS 数据评估与复发无关的残疾进展的可能指标。
TOP 是一项正在进行的、前瞻性、开放性标签的 RRMS 患者研究,患者接受静脉注射 300mg 那他珠单抗每 4 周一次。使用参考基线评分或“漫游”系统来评估残疾加重的指标,该系统在新评分确认 ⩾24 或 ⩾48 周后重置参考评分。
本分析纳入了 5562 例患者。与使用固定参考基线评分相比,使用漫游参考评分时,与复发无关的 EDSS 进展事件和总体 EDSS 恶化事件分别多检测出约 70%(累积概率:分别为 17.6%和 29.7%)和 50%(累积概率:分别为 10.1%和 20.3%)。
在这个长期的 RRMS 观察数据集,漫游 EDSS 参考值比研究基线 EDSS 参考值在检测与复发无关的进展/恶化事件方面更有效,从而可以更好地预测向继发进展性疾病的转变。